Locally Advanced Pancreatic Cancer Global Market Report 2025

The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and enhanced supportive care options.

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and improved supportive care options. Major trends include advancements in immunotherapy, the development of targeted therapies, enhanced precision radiation techniques, improvements in diagnostic imaging, the adoption of minimally invasive surgical approaches, the integration of artificial intelligence in treatment planning, and progress in combination therapy strategies.

The rising consumption of tobacco is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco, derived from plant leaves, is commonly used in products such as cigarettes and cigars and contains nicotine, a highly addictive substance linked to severe health conditions such as cancer and heart disease. Several factors, including easy access, affordability, tobacco marketing, social acceptance in certain regions, and stress-related smoking, have driven the increase in tobacco use. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in January 2024, according to Global Action to End Smoking, a US-based non-profit organization dedicated to ending the smoking epidemic, approximately 62.9 million adults in the U.S. used tobacco in 2022, making it the fourth-highest globally and the highest in the Americas. Additionally, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with a higher prevalence among males (13.1%) compared to females (10.1%). Consequently, the increase in tobacco consumption is driving the expansion of the locally advanced pancreatic cancer market.

Leading companies in the locally advanced pancreatic cancer market are prioritizing the development of innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically designed to treat rare conditions affecting a limited population and are supported by regulatory incentives, including tax benefits and market exclusivity, to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its drug Elraglusib, a novel GSK-3β inhibitor, had received Orphan Drug Designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential form of locally advanced pancreatic cancer. This designation underscores its potential to address a critical gap in treating this severe cancer, particularly following promising Phase 2 trial results that demonstrated significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen AstraZeneca’s oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development and manufacturing capabilities, and accelerating the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company that focuses on developing targeted therapies for various types of cancer, including pancreatic cancer.

Major players in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co.

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in locally advanced pancreatic cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the locally advanced pancreatic cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Locally advanced pancreatic cancer (LAPC) is a stage of pancreatic cancer in which the tumor remains confined to the pancreas and surrounding tissues but has not metastasized to distant organs. Due to its involvement with vital blood vessels or nearby structures, LAPC is typically not suitable for surgical removal.

The primary treatment options for locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy cancer cells or inhibit their growth. These therapies can be administered through various routes, including oral, injectable, and others, and are utilized in hospitals, specialty clinics, research institutes, and other healthcare settings.

The locally advanced pancreatic cancer market research report is one of a series of new reports that provides locally advanced pancreatic cancer market statistics, including the locally advanced pancreatic cancer industry's global market size, regional shares, competitors with a locally advanced pancreatic cancer market share, detailed locally advanced pancreatic cancer market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. This locally advanced pancreatic cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.